Medscape

Vedolizumab Reduces Postoperative Crohn’s Disease Recurrence

Vedolizumab treatment within 4 weeks of ileocolonic resection outperformed placebo in preventing postoperative endoscopic recurrence of Crohn’s disease in patients with at least one risk factor for ...
Seeking Alpha

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone WILMINGTON, Del.-- ...
Hosted on MSN

IMFINZI Combination Cuts Disease Recurrence Risk by 32% in Early Bladder Cancer Trial

WILMINGTON, DE — AstraZeneca announced that its IMFINZI (durvalumab) regimen significantly reduced the risk of disease recurrence or death by 32 percent in patients with high-risk, non-muscle-invasive ...
Healio

Older adults with Crohn’s at risk for postop recurrence, benefit from biologic prophylaxis

Please provide your email address to receive an email when new articles are posted on . Initiation of prophylactic biologics within 90 days of surgery was linked to reduced risk for recurrence among ...
Reuters

Roche breast cancer pill cuts risk of disease recurrence by 30% in trial

LONDON, Dec 10 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine ...
Business Wire

Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer

– ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment – – Data will be featured in ...

ctDNA levels after neoadjuvant therapy may predict breast cancer recurrence better than pathologic complete response

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive ...
Business Wire

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence ...

Data support routine use of circulating tumor DNA testing in management of stage III colon cancer patients Tumor fraction analysis provides further insights for patient management in patients with ...
clinicaladvisor.com

Recurrent Pneumonia in Children: Etiology, Risk Factors Differ by Area of Recurrence

The prevalence and risk factors for recurrent pneumonia differed between pediatric patients with recurrence in the same vs different areas, suggesting that data on the location of the recurrence may ...
Medscape

GLP-1s Don’t Raise DTC Recurrence Risk, Study Says

SCOTTSDALE, AZ — While most of the research on the role of GLP-1 receptor agonists (RAs) in thyroid cancer has focused on their potential to trigger such cancer, new research found that among patients ...